Send the following on WhatsApp
Continue to Chat信達生物與葆元醫藥宣布 ROS1 抑制劑他雷替尼第二項新藥上市申請獲中國國家藥品監督管理局受理,用於一線治療 ROS1 陽性肺癌 https://geneonline.news/%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e8%88%87%e8%91%86%e5%85%83%e9%86%ab%e8%97%a5%e5%ae%a3%e5%b8%83-ros1-%e6%8a%91%e5%88%b6%e5%8a%91%e4%bb%96%e9%9b%b7%e6%9b%bf%e5%b0%bc%e7%ac%ac%e4%ba%8c%e9%a0%85/?variant=zh-cn